Gly-beta-MCA

66225-78-3

C26H43NO6

DMSO : 125 mg/mL (268.46 mM; Need ultrasonic)

Metabolic Enzyme/Protease

Gly-beta-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders^[1]. IC50 & Target: FXR^[1]. In Vitro: Gly-beta-MCA, a bile acid, is a potent, sable and intestine-selective and farnesoid X receptor (FXR) inhibitor^[1].
Gly-beta-MCA (Gly-MCA, ) is resistant to hydrolysis by BSH^[1]. In Vivo: Gly-beta-MCA (Gly-MCA, p.o. 10 and 50 mg/kg) prevents and treats diet-induced and genetic obesity, along with insulin resistance and hepatic steatosis without systemic, hepatic or intestinal toxicities in mice^[1].
Gly-MCA does not increase faecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation^[1].